Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on United Therapeutics (NASDAQ:UTHR) and Ionis Pharmaceuticals Inc (NASDAQ:IONS).
United Therapeutics (UTHR)
Wedbush analyst Liana Moussatos reiterated a Buy rating on United Therapeutics today and set a price target of $253. The company’s shares opened today at $124.83.
According to TipRanks.com, Moussatos is a 3-star analyst with an average return of 2.4% and a 42.5% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Catabasis Pharmaceuticals, and Global Blood Therapeutics.
Currently, the analyst consensus on United Therapeutics is a Hold with an average price target of $139.50, implying an 11.8% upside from current levels. In a report issued on August 1, Oppenheimer also assigned a Buy rating to the stock with a $160 price target.
.
See today’s analyst top recommended stocks >>
Ionis Pharmaceuticals Inc (IONS)
Cowen & Co. analyst Ritu Baral maintained a Hold rating on Ionis Pharmaceuticals Inc today. The company’s shares opened today at $43.36, close to its 52-week low of $39.07.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 34.5% and a 56.1% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Global Blood Therapeutics.
Currently, the analyst consensus on Ionis Pharmaceuticals Inc is a Hold with an average price target of $47.33, which is a 9.2% upside from current levels. In a report released yesterday, Stifel Nicolaus also initiated coverage with a Hold rating on the stock with a $47 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
